Country: United States
Language: English
Source: NLM (National Library of Medicine)
NITRIC OXIDE (UNII: 31C4KY9ESH) (NITRIC OXIDE - UNII:31C4KY9ESH)
HumanEnos LLC
TOPICAL
OTC DRUG
Hexalong N:O Hexalong N:O
unapproved drug other
HEXALONG NO (HELPS HEMATOPOIESIS AND IMMUNITY, HEXALONG FERMENTED POWDER)- NITRIC OXIDE, ZINC, VITAMIN D3 TABLET HUMANENOS LLC _Disclaimer: This drug has not been found by FDA to be safe and effective, and this_ _labeling has not been approved by FDA. For further information about unapproved_ _drugs, click here._ ---------- HEXALONG NO (HELPS HEMATOPOIESIS AND IMMUNITY, HEXALONG FERMENTED POWDER) 500 mg X 120 / 2.12 oz KEEP OUT OF THE REACH OF CHILDREN. Hexalong N:O Warnings Hexalong N:O Inactive ingredients: Corn Starch, Dietary fiber, beet red concentratd powder Active ingredients: Nitric Oxide, Zinc, Vitamin D3 HEXALONG NO (HELPS HEMATOPOIESIS AND IMMUNITY, HEXALONG FERMENTED POWDER) nitric oxide, zinc, vitamin d3 tablet PRODUCT INFORMATION PRODUCT TYPE HUMAN OTC DRUG ITEM CODE (SOURCE) NDC:83202-5578 ROUTE OF ADMINISTRATION TOPICAL ACTIVE INGREDIENT/ACTIVE MOIETY INGREDIENT NAME BASIS OF STRENGTH STRENGTH HumanEnos LLC NITRIC OXIDE (UNII: 31C4KY9ESH) (NITRIC OXIDE - UNII:31C4KY9ESH) NITRIC OXIDE 100 mg in 500 mg INACTIVE INGREDIENTS INGREDIENT NAME STRENGTH BEET (UNII: N487KM8COK) 1 mg in 500 mg MODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE) (UNII: 461P5CJN6T) 1 mg in 500 mg PRODUCT CHARACTERISTICS COLOR white SCORE score with uneven pieces SHAPE CAPSULE SIZE 500mm FLAVOR FRUIT IMPRINT CODE tablet CONTAINS PACKAGING # ITEM CODE PACKAGE DESCRIPTION MARKETING START DATE MARKETING END DATE 1 NDC:83202- 5578-2 120 mg in 1 PACKAGE; Type 0: Not a Combination Product 02/13/2024 02/12/2025 MARKETING INFORMATION MARKETING CATEGORY APPLICATION NUMBER OR MONOGRAPH CITATION MARKETING START DATE MARKETING END DATE unapproved drug other 02/13/2024 02/12/2025 LABELER - HumanEnos LLC (695801540) ESTABLISHMENT NAME ADDRESS ID/FEI BUSINESS OPERATIONS HumanEnos LLC 695801540 manufacture(83202-5578) Revised: 2/2024 Read the complete document